These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
326 related articles for article (PubMed ID: 33012018)
1. Upregulation of the long noncoding RNAs DSCAM-AS1 and MANCR is a potential diagnostic marker for breast carcinoma. Tahmouresi F; Razmara E; Pakravan K; Mossahebi-Mohammadi M; Rouhollah F; Montazeri M; Sarrafzadeh A; Fahimi H; Babashah S Biotechnol Appl Biochem; 2021 Dec; 68(6):1250-1256. PubMed ID: 33012018 [TBL] [Abstract][Full Text] [Related]
2. The clinical significance of circulating DSCAM-AS1 in patients with ER-positive breast cancer and construction of its competitive endogenous RNA network. Moradi MT; Fallahi H; Rahimi Z Mol Biol Rep; 2020 Oct; 47(10):7685-7697. PubMed ID: 33040318 [TBL] [Abstract][Full Text] [Related]
3. DSCAM-AS1 promotes tumor growth of breast cancer by reducing miR-204-5p and up-regulating RRM2. Liang WH; Li N; Yuan ZQ; Qian XL; Wang ZH Mol Carcinog; 2019 Apr; 58(4):461-473. PubMed ID: 30457164 [TBL] [Abstract][Full Text] [Related]
4. Long non-coding RNA (lncRNA) DSCAM-AS1 is upregulated in breast cancer. Tarighi M; Khalaj-Kondori M; Hosseinzadeh A; Abtin M Breast Dis; 2021; 40(2):63-68. PubMed ID: 33554879 [TBL] [Abstract][Full Text] [Related]
5. DSCAM-AS1 up-regulation in invasive ductal carcinoma of breast and assessment of its potential as a diagnostic biomarker. Khorshidi H; Azari I; Oskooei VK; Taheri M; Ghafouri-Fard S Breast Dis; 2019; 38(1):25-30. PubMed ID: 30594914 [TBL] [Abstract][Full Text] [Related]
6. LncRNA DSCAM-AS1 interacts with YBX1 to promote cancer progression by forming a positive feedback loop that activates FOXA1 transcription network. Zhang Y; Huang YX; Wang DL; Yang B; Yan HY; Lin LH; Li Y; Chen J; Xie LM; Huang YS; Liao JY; Hu KS; He JH; Saw PE; Xu X; Yin D Theranostics; 2020; 10(23):10823-10837. PubMed ID: 32929382 [No Abstract] [Full Text] [Related]
7. LncRNA ST8SIA6-AS1 promotes proliferation, migration and invasion in breast cancer through the p38 MAPK signalling pathway. Fang K; Hu C; Zhang X; Hou Y; Gao D; Guo Z; Li L Carcinogenesis; 2020 Sep; 41(9):1273-1281. PubMed ID: 31784750 [TBL] [Abstract][Full Text] [Related]
8. LncRNA DSCAM-AS1: A Pivotal Therapeutic Target in Cancer. Hu C Mini Rev Med Chem; 2023; 23(5):530-536. PubMed ID: 35996247 [TBL] [Abstract][Full Text] [Related]
9. The potential roles of lncRNAs DUXAP8, LINC00963, and FOXD2-AS1 in luminal breast cancer based on expression analysis and bioinformatic approaches. Arabpour M; Layeghi SM; Bazzaz JT; Naghizadeh MM; Majidzadeh-A K; Shakoori A Hum Cell; 2021 Jul; 34(4):1227-1243. PubMed ID: 34043149 [TBL] [Abstract][Full Text] [Related]
10. The Expression Patterns and Implications of Syllaios A; Gazouli M; Vailas M; Mylonas KS; Sakellariou S; Sougioultzis S; Karavokyros I; Liakakos T; Schizas D Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203269 [TBL] [Abstract][Full Text] [Related]
11. Systematic analysis of lncRNA-miRNA-mRNA competing endogenous RNA network identifies four-lncRNA signature as a prognostic biomarker for breast cancer. Fan CN; Ma L; Liu N J Transl Med; 2018 Sep; 16(1):264. PubMed ID: 30261893 [TBL] [Abstract][Full Text] [Related]
12. Long noncoding RNA DSCAM-AS1 is associated with poor clinical prognosis and contributes to melanoma development by sponging miR-136. Huang YL; Xu Q; Wang X Eur Rev Med Pharmacol Sci; 2019 Apr; 23(7):2888-2897. PubMed ID: 31002140 [TBL] [Abstract][Full Text] [Related]
13. Long non-coding RNA DSCAM-AS1 indicates a poor prognosis and modulates cell proliferation, migration and invasion in ovarian cancer via upregulating SOX4. Li Y; Hao J; Jiang YM; Liu Y; Zhang SH Eur Rev Med Pharmacol Sci; 2019 May; 23(10):4143-4148. PubMed ID: 31173284 [TBL] [Abstract][Full Text] [Related]
14. Study on expression of lncRNA RGMB-AS1 and repulsive guidance molecule b in non-small cell lung cancer. Li P; Li J; Yang R; Zhang F; Wang H; Chu H; Lu Y; Dun S; Wang Y; Zang W; Du Y; Chen X; Zhao G; Zhang G Diagn Pathol; 2015 Jun; 10():63. PubMed ID: 26055877 [TBL] [Abstract][Full Text] [Related]
15. Quantitative Expression of Rishehri M; Etemadi T; Pisheh L; Koufigar G; Azadeh M Genet Res (Camb); 2022; 2022():6787791. PubMed ID: 36160032 [TBL] [Abstract][Full Text] [Related]
16. Mitotically-Associated lncRNA (MANCR) Affects Genomic Stability and Cell Division in Aggressive Breast Cancer. Tracy KM; Tye CE; Ghule PN; Malaby HLH; Stumpff J; Stein JL; Stein GS; Lian JB Mol Cancer Res; 2018 Apr; 16(4):587-598. PubMed ID: 29378907 [TBL] [Abstract][Full Text] [Related]
17. Serum LncRNA-ATB and FAM83H-AS1 as diagnostic/prognostic non-invasive biomarkers for breast cancer. El-Ashmawy NE; Hussien FZ; El-Feky OA; Hamouda SM; Al-Ashmawy GM Life Sci; 2020 Oct; 259():118193. PubMed ID: 32763293 [TBL] [Abstract][Full Text] [Related]
18. Long noncoding RNA DSCAM-AS1 functions as an oncogene in non-small cell lung cancer by targeting BCL11A. Liao J; Xie N Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1087-1092. PubMed ID: 30779076 [TBL] [Abstract][Full Text] [Related]
19. DSCAM-AS1 mediates pro-hypertrophy role of GRK2 in cardiac hypertrophy aggravation via absorbing miR-188-5p. Chen H; Cai K In Vitro Cell Dev Biol Anim; 2020 Apr; 56(4):286-295. PubMed ID: 32377998 [TBL] [Abstract][Full Text] [Related]
20. Silencing DSCAM-AS1 suppresses the growth and invasion of ER-positive breast cancer cells by downregulating both DCTPP1 and QPRT. Yue Z; Shusheng J; Hongtao S; Shu Z; Lan H; Qingyuan Z; Shaoqiang C; Yuanxi H Aging (Albany NY); 2020 Jul; 12(14):14754-14774. PubMed ID: 32716908 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]